



SDI Review Form 1.6

Journal Name:	International Journal of Biochemistry Research & Review
Manuscript Number:	Ms_IJBCRR_23216
Title of the Manuscript:	Optimizing the aggregation propensity of therapeutic monoclonal antibodies against cancer and autoimmune diseases: a computational study
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<u>Compulsory</u> REVISION comments		
<u>Minor</u> REVISION comments	Using a computational study, this manuscript show how by the modification of some amino acids, it is possible to increase the solubility of monoclonal antibodies. The development and current use of computational studies it turns vital in order to decrease any possible toxic effects and increase effectiveness of monoclonal antibodies. These systems will allow to determinate the most likely areas to form aggregates and determine the type of amino acid substitutions necessary to reduce such risk. However, it is hard to elucidate if such modifications made in the antibodies can modify their availability, union or antigenicity characteristics. Although this is not the gold of the study, it is very important to realize the suitable experiments to probe the scope of this study.	We thank the reviewer for his/hers comments. This is properly acknowledged in the "Acknowledgements" section. We emphasize in the "Discussion" section that suitable experiments should be performed to experimentally test the monoclonal antibody variants predicted from this study, in the revised version hereby submitted.
<u>Optional/General</u> comments		